Researchers track Real-World results of breast cancer drug in israel
NCT ID NCT04671615
Summary
This study observed how the breast cancer drug palbociclib was used and how patients responded in real-world healthcare settings in Israel. Researchers followed 559 adults with metastatic breast cancer who were already receiving palbociclib as part of their standard care. The goal was to understand treatment patterns, how long patients stayed on the drug, and what happened after treatment ended, without testing any new treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Pharmaceuticals Israel Ltd.
Herzliya Pituah, 4672509, Israel
Conditions
Explore the condition pages connected to this study.